We are live on ! Find out more
OPRX icon

OptimizeRx

97 hedge funds and large institutions have $155M invested in OptimizeRx in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 38 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,662% more call options, than puts

Call options by funds: $229K | Put options by funds: $13K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

1.16% more ownership

Funds ownership: 69.26%70.42% (+1.2%)

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1% less funds holding

Funds holding: 9897 (-1)

14% less capital invested

Capital invested by funds: $180M → $155M (-$24.5M)

37% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 38

Holders
97
Holders Change
-1
Holders Change %
-1.02%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
16
Increased
24
Reduced
38
Closed
17
Calls
$229K
Puts
$13K
Net Calls
+$216K
Net Calls Change
-$3.16M
Name Holding Trade Value Shares
Change
Change in
Stake
CIS
51
Connors Investor Services
Pennsylvania
$202K -$114K -7,893 -32%
UBS Group
52
UBS Group
Switzerland
$194K +$16.1K +1,110 +7%
PFM
53
Premier Fund Managers
United Kingdom
$188K +$225K +15,511 New
Goldman Sachs
54
Goldman Sachs
New York
$176K +$16K +1,104 +8%
Two Sigma Advisers
55
Two Sigma Advisers
New York
$157K -$321K -22,100 -63%
ECM
56
ExodusPoint Capital Management
New York
$138K +$164K +11,341 New
Group One Trading
57
Group One Trading
Illinois
$136K +$163K +11,218 New
CFM
58
Catalyst Funds Management
Australia
$135K +$162K +11,150 New
Barclays
59
Barclays
United Kingdom
$135K -$161K -11,074 -50%
HIM
60
Hillsdale Investment Management
Ontario, Canada
$130K -$72.5K -5,000 -32%
MIM
61
MetLife Investment Management
New Jersey
$111K
Qube Research & Technologies (QRT)
62
Qube Research & Technologies (QRT)
United Kingdom
$100K +$120K +8,251 New
Deutsche Bank
63
Deutsche Bank
Germany
$96.7K -$4.57K -315 -4%
AIG
64
American International Group
New York
$95.5K -$2.58K -178 -2%
Wells Fargo
65
Wells Fargo
California
$94.6K +$8.46K +583 +8%
SOW
66
State of Wyoming
Wyoming
$65.9K +$20K +1,378 +34%
Simplex Trading
67
Simplex Trading
Illinois
$65K -$191K -13,173 -71%
QT
68
Quantbot Technologies
New York
$63.9K +$9.8K +676 +15%
New York State Common Retirement Fund
69
New York State Common Retirement Fund
New York
$61.2K -$102 -7 -0.1%
Fidelity Investments
70
Fidelity Investments
Massachusetts
$33.7K -$1.45K -100 -3%
Citigroup
71
Citigroup
New York
$32K +$5.54K +382 +17%
Nisa Investment Advisors
72
Nisa Investment Advisors
Missouri
$26.1K +$73 +5 +0.2%
AT
73
Avalon Trust
New Mexico
$24.3K
Osaic Holdings
74
Osaic Holdings
Arizona
$21.6K -$41.4K -2,853 -62%
Legal & General Group
75
Legal & General Group
United Kingdom
$20.8K

OPRX Hedge Fund Activity: Q1 2024 in Review

97 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q1 2024, worth a combined $155M — down 14% from $180M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of OPRX and 16 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 24 added.

The largest buyer was Divisadero Street Capital Management, adding an estimated $9.04M. The largest seller was Kennedy Capital Management, cutting an estimated $2.48M.

  • 97 institutional investors held OptimizeRx (OPRX) as of Q1 2024, down from 98 in Q4 2023.
  • Funds reported $155M of OptimizeRx stock for Q1 2024, down 14% quarter-over-quarter.
  • 16 funds opened new OptimizeRx positions in Q1 2024 and 17 closed out, a net change of -1 holder.
  • The largest OptimizeRx buyer in Q1 2024 was Divisadero Street Capital Management, an estimated $9.04M added.
  • The largest OptimizeRx seller in Q1 2024 was Kennedy Capital Management, an estimated $2.48M sold.

Based on aggregated 13F filings for Q1 2024.